Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain
NCT01288937 · Columbia University · PHASE3 · terminated · last registry update 2020-09-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Poor recruitment” | – | Registry record, Columbia University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-08-02Phase 3 first posted: Intra-Cellular Therapies, Inc., Lumateperone + Placebo (NCT04985942)
- 2021-07-22Phase 3 first posted: New York State Psychiatric Institute, Venlafaxine HCl ER (NCT04973930)
- 2021-07-12Phase 3 first posted: Intra-Cellular Therapies, Inc., Lumateperone 42 mg + Placebo (NCT04959032)
- 2021-04-01Results posted on the registry: New York State Psychiatric Institute, Fluoxetine + Citalopram (NCT02473250)
- 2021-03-29Results posted on the registry: University of Texas Southwestern Medical Center, Naltrexone: Vivitrol® + Placebo (PLB) Injectable (NCT03078075)
- 2021-02-18Phase 3 first posted: Children's Hospital Los Angeles, Fluoxetine (NCT04760275)
- 2021-01-27Phase 3 first posted: Cardresearch, Budesonide Powder + Fluoxetine 20 MG (NCT04727424)
- 2020-10-22Phase 3 first posted: Ann & Robert H Lurie Children's Hospital of Chicago, Combination therapy (COMB) (NCT04598230)
- 2020-04-14Phase 3 first posted: Mochida Pharmaceutical Company, Ltd., Desvenlafaxine 100 mg + Desvenlafaxine 50 mg (NCT04345471)
- 2020-03-10Phase 3 first posted: University of Edinburgh, Memantine Hydrochloride Oral Solution + Trazodone Hydrochloride oral solution (NCT04302870)
- 2020-02-26Phase 3 first posted: Intra-Cellular Therapies, Inc., Lumateperone + Placebos (NCT04285515)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision